Home
About
Overview
Sharing Data
ORCID
Help
History (15)
Reassessing the risks and benefits of thiopurines in Crohn's disease.
Expanded Physiological Testing of the Lower Urinary Tract in Asymptomatic Women and Those With Urgency Urinary Incontinence: Findings From the LURN-Organ Study.
Gravidity, parity, blood pressure and mortality among women in Bangladesh from the HEALS cohort.
Principal Investigator
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32.
View in:
PubMed
subject areas
Crohn Disease
Double-Blind Method
Drug Administration Schedule
Humans
Injections, Subcutaneous
Maintenance Chemotherapy
Treatment Outcome
Ustekinumab
authors with profiles
Stephen B. Hanauer